Loading clinical trials...
Loading clinical trials...
DRAGON III research, Neoadjuvant Chemotherapy (FLOT versus SOX) for Gastric Cancer, is an investigator initiated; phase 3, open label, multi-center randomized controlled study.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Ruijin Hospital
NCT07660627 · Esophageal Adenocarcinoma, Gastric Cancer, and more
NCT07432633 · Colorectal Cancer, Epithelial Ovarian Cancer, and more
NCT06764875 · HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
NCT07431281 · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, and more
NCT05872295 · Breast Cancer, Gastric Cancer, and more
Ruijin Hospital Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions